16.47
0.14 (0.86%)
| Penutupan Terdahulu | 16.33 |
| Buka | 16.34 |
| Jumlah Dagangan | 1,132,430 |
| Purata Dagangan (3B) | 1,098,176 |
| Modal Pasaran | 1,213,257,600 |
| Harga / Jualan (P/S) | 4.87 |
| Harga / Buku (P/B) | 3.92 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Keuntungan | -83.39% |
| Margin Operasi (TTM) | -85.45% |
| EPS Cair (TTM) | -2.63 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 62.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 31.15% |
| Nisbah Semasa (MRQ) | 3.45 |
| Aliran Tunai Operasi (OCF TTM) | 25.97 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -17.73 M |
| Pulangan Atas Aset (ROA TTM) | -16.27% |
| Pulangan Atas Ekuiti (ROE TTM) | -43.33% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Health Information Services (US) | Menurun | Bercampur |
| Health Information Services (Global) | Menurun | Bercampur | |
| Stok | Schrodinger, Inc. | Menaik | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -4.0 |
| Purata | 1.00 |
|
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations. |
|
| Sektor | Healthcare |
| Industri | Health Information Services |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.63% |
| % Dimiliki oleh Institusi | 101.76% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Gates Foundation Trust | 30 Sep 2025 | 6,981,664 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 28.00 (Keybanc, 70.01%) | Beli |
| Median | 23.50 (42.68%) | |
| Rendah | 19.00 (Goldman Sachs, 15.36%) | Pegang |
| Purata | 23.50 (42.68%) | |
| Jumlah | 1 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 20.39 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Keybanc | 08 Oct 2025 | 28.00 (70.01%) | Beli | 20.72 |
| Goldman Sachs | 30 Sep 2025 | 19.00 (15.36%) | Pegang | 20.06 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 Nov 2025 | Pengumuman | Schrödinger to Present at Jefferies London Healthcare Conference |
| 05 Nov 2025 | Pengumuman | Schrödinger Reports Third Quarter 2025 Financial Results |
| 22 Oct 2025 | Pengumuman | Schrödinger to Announce Third Quarter 2025 Financial Results on November 5 |
| 15 Oct 2025 | Pengumuman | Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 18 Sep 2025 | Pengumuman | Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |